Stories from people navigating Heart Failure — diagnosis, treatment, caregiving, and the ordinary days in between.
9 stories
Cardiology
Across randomized heart-failure trials, SGLT2 inhibitors most reliably reduce worsening heart failure and cardiovascular death. Evidence for lower all-cause mortality is less secure.
Rayan Salih · September 21, 2026 · 7 min
Cardiology
A 2026 meta-analysis found that digitalis glycosides reduced worsening heart failure events, but not cardiovascular death, reinforcing a selective rather than routine role.
Dr. Abu Bakar · 7 min read
Cardiology
In a randomized trial, acoramidis preserved patient-reported health status and reduced cardiovascular hospitalizations over 30 months in adults with transthyretin amyloid cardiomyopathy.
Rayan Salih · 7 min read
Cardiology
FINEARTS-HF found that baseline blood pressure did not materially alter finerenone’s effect on cardiovascular death and total worsening heart failure events in patients with LVEF of 40% or higher.
Rayan Salih · 6 min read
Endocrinology & Metabolism
Updated evidence supports SGLT inhibition across heart failure phenotypes, with the clearest benefit in preventing worsening heart failure. Mortality and safety findings require more nuanced interpretation.
Dr. Abu Bakar · 7 min read
Cardiology
The 2026 consensus sharpens how heart failure should be identified and documented when symptoms, cardiac abnormalities, biomarkers and evidence of congestion disagree.
Rayan Salih · 7 min read
Cardiology
Left ventricular systolic dysfunction is the heart problem behind many cases of heart failure, and it often develops
Dr. Abu Bakar · 7 min read
Cardiology
Advanced heart failure is not defined by one test or one number.
Dr. Abu Bakar · 7 min read
Cardiology
Preliminary human experience with the smart device for heart failure decongestion will also be presented.
Dr. Abu Bakar · 12 min read
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.